Choose Your News
* Farxiga cuts hospitalisation for heart failure and CV death... [Read More]
* European Humira sales around $4.4 bln a year (Adds details on biosimilars market in Europe, graphic) [Read More]
WUXI, China/ LONDON, Sept 19- With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca... [Read More]
*Horlicks unit offers big footprint in Indian market. LONDON, Sept 18- Nestle, Unilever and Coca-Cola are among bidders for GlaxoSmithKline's Indian Horlicks nutrition business, expected... [Read More]
BRITAIN-EU/ROCHE (PIX):Roche boss says Brexit and curbs on drug use pose threat to UK science... [Read More]
European medicines regulators have issued a notice that an ingredient for a generic brain cancer drug made in China does not meet manufacturing standards, after... [Read More]
* Green light shows growing strength of Chinese biotech (Updates with CEO interview, latest shares, background) [Read More]
British scientists have unravelled how a non-intoxicating component of cannabis acts in key brain areas to reduce abnormal activity in patients at risk of psychosis,... [Read More]
A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain's state-funded health service, the... [Read More]
BRITAIN-EU/PHARMACEUTICALS (PIX):UK calls for extra six weeks of Brexit drug stockpiles... [Read More]
* GSK hopes to gain market share from market leader Gilead (Updates with latest GSK and Gilead share price moves) [Read More]
A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting... [Read More]
* IPO to give Sensyne post-money value of around 225 mln pounds... [Read More]
How much is your DNA worth? As millions of people pay for home tests to check on ancestry or health risks, genetic data is becoming... [Read More]
The European Medicines Agency (EMA) is to scale back operations further as it copes with higher than expected staff losses, triggered by the watchdog's forced... [Read More]
* Shares rise more than 2 pct (Adds analyst reaction, further CEO quotes, U.S. pricing comment) [Read More]
* Double-digit growth in emerging markets, led by China (Adds CEO comment, details on drug sales, shares) [Read More]
* Pharma R&D turnaround top priority for British group (Adds Breakingviews link, further CEO quote on group structure) [Read More]
* Pharma R&D turnaround top priority for British group (Adds further CEO comments) [Read More]
* Pharma R&D turnaround top priority for British group (Updates with more on outlook, shares) [Read More]